Scientific work

Prof. Dr. Hüseyin Mertsoylu

113 publications. The source of the information is stated next to each publication.

Back to profile

  1. Comment on: Does the Planning Target Volume Correlate with Toxicity for Head and Neck Cancer Patients Undergoing Radiation? A Prospective Observational Study

    Indian Journal of Surgical Oncology, 2024

    DOI 10.1007/s13193-024-02045-2 PMID 39328732 1 citation (Europe PMC) Open-access full textSource: ORCID

  2. Novel Index Combining Pan‐Immune‐Inflammatory Index and Hemoglobin Levels (PIV/Hb) Predicts Trismus Rates Efficiently after Chemoradiotherapy in Locally Advanced Nasopharyngeal Cancer

    International Journal of Surgical Oncology, 2024

    DOI 10.1155/2024/2124006 PMID 39376995 2 citations (Europe PMC) Open-access full textSource: ORCID

  3. Letter to Editor: “The Trajectory of Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiotherapy and Its Influencing Factors”

    Ear, Nose and Throat Journal, 2024

    DOI 10.1177/01455613241249268 PMID 38656170 Open-access full textSource: ORCID

  4. Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients

    Journal of Stomatology, Oral and Maxillofacial Surgery, 2024

    DOI 10.1016/j.jormas.2024.101838 PMID 38518893 2 citations (Europe PMC) Source: ORCID

  5. Predictive potential of pan-immune-inflammation value / hemoglobin index as biomarker for osteoradionecrosis risk in locally advanced nasopharyngeal carcinomas

    Journal of Stomatology, Oral and Maxillofacial Surgery, 2024

    DOI 10.1016/j.jormas.2024.101786 PMID 38286220 1 citation (Europe PMC) Source: ORCID

  6. The Use of Pre-Chemoradiotherapy Total Masseter Muscle Volume as a Novel Predictor of Radiation-Induced Trismus in Locally Advanced Nasopharyngeal Carcinoma Patients

    Tomography, 2024

    DOI 10.3390/tomography10010007 PMID 38250953 2 citations (Europe PMC) Open-access full textSource: ORCID

  7. The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol

    International Journal of Immunopathology and Pharmacology, 2024

    DOI 10.1177/03946320241284089 PMID 39305006 5 citations (Europe PMC) Open-access full textSource: ORCID

  8. Worth of pan-immune-inflammation value in trismus prediction after concurrent chemoradiotherapy for nasopharyngeal carcinomas

    International Journal of Biological Markers, 2024

    DOI 10.1177/03936155231223198 PMID 38192114 9 citations (Europe PMC) Open-access full textSource: ORCID

  9. The Predictive Power of Biomarkers in Osteoradionecrosis

    Interdisciplinary cancer research, 2024

    DOI 10.1007/16833_2024_266 2 citations (OpenAlex) Source: OpenAlex

  10. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

    Discover Oncology, 2023

    DOI 10.1007/s12672-023-00851-8 PMID 38091179 5 citations (Europe PMC) Open-access full textSource: ORCID

  11. Predicting Teeth Extraction after Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Cancer Patients Using the Novel GLUCAR Index

    Diagnostics, 2023

    DOI 10.3390/diagnostics13233594 PMID 38066835 13 citations (Europe PMC) Open-access full textSource: ORCID

  12. Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy

    Journal of Clinical Medicine, 2023

    DOI 10.3390/jcm12216863 PMID 37959329 4 citations (Europe PMC) Open-access full textSource: ORCID

  13. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

    Cancers, 2023

    DOI 10.3390/cancers15184512 PMID 37760482 22 citations (Europe PMC) Open-access full textSource: ORCID

  14. A Comprehensive Review of Differences between Osteoradionecrosis and Medication-related Osteonecrosis of the Jaw

    Journal of Cancer and Tumor International, 2023

    DOI 10.9734/jcti/2023/v13i1229 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  15. Kanser ve Enfeksiyon

    Akademisyen Kitabevi eBooks, 2023

    DOI 10.37609/akya.2853 Open-access full textSource: OpenAlex

  16. Onkolojide İmmünoterapi

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1749 Source: OpenAlex

  17. Onkolojide Güncel Tedavi Yaklaşımları 1

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1606 Source: OpenAlex

  18. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients

    Therapeutics and Clinical Risk Management, 2022

    DOI 10.2147/tcrm.s359553 PMID 35444422 5 citations (Europe PMC) Open-access full textSource: ORCID

  19. Sarkomlar ve Cilt Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1097 Open-access full textSource: OpenAlex

  20. Toraks Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1073 Open-access full textSource: OpenAlex

  21. Baş Boyun ve Santral Sinir Sistemleri Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1075 Open-access full textSource: OpenAlex

  22. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck

    Cancer Chemotherapy and Pharmacology, 2021

    DOI 10.1007/s00280-021-04328-9 PMID 34312705 1 citation (Europe PMC) Source: OpenAlex

  23. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients with HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study

    American Journal of Clinical Oncology: Cancer Clinical Trials, 2021

    DOI 10.1097/coc.0000000000000825 PMID 33979100 17 citations (Europe PMC) Source: ORCID

  24. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy

    Ear, Nose and Throat Journal, 2021

    DOI 10.1177/0145561319856327 PMID 31184210 10 citations (Europe PMC) Open-access full textSource: ORCID

  25. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis

    Journal of Oncology, 2021

    DOI 10.1155/2021/6688138 PMID 33552158 16 citations (Europe PMC) Open-access full textSource: ORCID

  26. Pretreatment Photopenia on 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scans Predicts Poor Prognosis in Nasopharyngeal Cancer Patients Undergoing Concurrent Chemoradiotherapy

    Clinical and Experimental Otorhinolaryngology, 2020

    DOI 10.21053/ceo.2019.01298 PMID 32075362 Open-access full textSource: ORCID

  27. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy

    Gastroenterology Research and Practice, 2020

    DOI 10.1155/2020/5701949 PMID 32802045 29 citations (Europe PMC) Open-access full textSource: ORCID

  28. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide

    International Journal of Inflammation, 2020

    DOI 10.1155/2020/6947382 PMID 32566124 9 citations (Europe PMC) Open-access full textSource: ORCID

  29. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy

    Cancer Management and Research, 2020

    DOI 10.2147/cmar.s248034 PMID 32214853 22 citations (Europe PMC) Open-access full textSource: ORCID

  30. A Phase Ii Study Of The Combination Of Oxaliplatin, Capecitabine, And Trastuzumab And Chem-oradiotherapy In The Adjuvant Setting In Operated Patients With Her2+ Gastric Or Gastroesophageal Junction Cancer (Toxag Study), A Turkish Oncology Group Study

    Research Square, 2020

    DOI 10.21203/rs.3.rs-16111/v1 Open-access full textSource: ORCID

  31. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse

    European Journal of Gynaecological Oncology, 2020

    DOI 10.31083/j.ejgo.2020.06.5344 Open-access full textSource: ORCID

  32. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study

    Journal of Oncology, 2020

    DOI 10.1155/2020/7083149 PMID 32952557 8 citations (Europe PMC) Open-access full textSource: ORCID

  33. Half-dose bevacizumab experience in relapsed ovarian cancer patients in Turkey due to formal regulations: similar effectiveness with lower rate of hypertension

    Journal of B.U.ON., 2020

    PMID 33099934 7 citations (OpenAlex) Source: ORCID

  34. Low advanced lung cancer inflammation index predicts poor prognosis in locally advanced nasopharyngeal carcinoma patients treated with definitive concurrent chemoradiotherapy

    Journal of Oncology, 2020

    DOI 10.1155/2020/3127275 PMID 33082783 10 citations (Europe PMC) Open-access full textSource: ORCID

  35. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide

    Mediators of Inflammation, 2020

    DOI 10.1155/2020/4392189 PMID 32565725 22 citations (Europe PMC) Open-access full textSource: ORCID

  36. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol

    Journal of Immunology Research, 2020

    DOI 10.1155/2020/8628540 PMID 33274245 36 citations (Europe PMC) Open-access full textSource: ORCID

  37. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

    Journal of Oncology, 2020

    DOI 10.1155/2020/8832145 PMID 33381177 13 citations (Europe PMC) Open-access full textSource: ORCID

  38. AKCİĞER KANSERİ EPİDEMİYOLOJİ VE ETYOPATOGENEZİ

    2020

    Source: OpenAlex

  39. Kanser Hastalarında Kemik ve Kas Sağlığı

    Turkiye Klinikleri Medical Oncology - Special Topics, 2020

    Source: OpenAlex

  40. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

    Future oncology (London, England), 2019

    DOI 10.2217/fon-2018-0635 PMID 30977383 9 citations (Europe PMC) Source: ORCID

  41. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2019

    DOI 10.1007/s00066-019-01429-6 PMID 30701292 8 citations (Europe PMC) Source: ORCID

  42. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.7_suppl.308 2 citations (OpenAlex) Source: ORCID

  43. The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.7_suppl.316 1 citation (OpenAlex) Source: ORCID

  44. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy

    International Journal of Biological Markers, 2019

    DOI 10.1177/1724600818821688 PMID 30864463 17 citations (Europe PMC) Open-access full textSource: ORCID

  45. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse

    Leukemia Research, 2019

    DOI 10.1016/s0145-2126(19)30279-6 Source: ORCID

  46. Initial presentation of prostate cancer may hint different clinical characteristics along with serving predictive biomarker in castration-resistant prostate cancer patients treated with abiraterone acetate

    Leukemia Research, 2019

    DOI 10.1016/s0145-2126(19)30281-4 Source: ORCID

  47. Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy

    Cancer Management and Research, 2019

    DOI 10.2147/cmar.s222297 PMID 31632140 29 citations (Europe PMC) Open-access full textSource: ORCID

  48. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy

    Journal of Geriatric Oncology, 2019

    DOI 10.1016/j.jgo.2018.10.014 PMID 31178158 7 citations (Europe PMC) Source: ORCID

  49. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients

    PLoS ONE, 2019

    DOI 10.1371/journal.pone.0218627 PMID 31329602 10 citations (Europe PMC) Open-access full textSource: ORCID

  50. Treatment outcomes of early stage endometrial cancer patients: single center experience

    Cukurova Medical Journal, 2019

    DOI 10.17826/cumj.491549 Open-access full textSource: ORCID